Securities Investors Association (Singapore)
7 Maxwell Road #05-03 MND Building Annexe B Singapore 069111
Tel: (65) 6227 2683 Fax: (65) 6220 6614
Email: admin@sias.org.sg www.sias.org.sg
UEN No: S99SS0111B
GST Reg No: M90367530Y

Issuer: TalkMed Group Limited

Stock code: 5G3

Meeting details:
Date: 20 April 2020
Time: 6.00 p.m.

Due to the current COVID-19 pandemic, SIAS encourage shareholders to participate at AGMs via other means and not to attend any AGM physically. Where the AGM is webcast, they can stay on top of their investments by watching the webcast and submitting their question to the company in advance. Senior citizens should avoid attending AGMs altogether and stay home.

Company Description

TalkMed Group Limited is a Singapore-based investment holding company. The Company's principal activities are the provision of medical oncology services and stem cell transplant services. The Company's segments include Oncology services and Stem cells services. Its doctors provide tertiary healthcare services in the fields of medical oncology, stem cell transplant and palliative care to the oncology patients in the private sector in Singapore through Parkway Cancer Centre (PCC). Its clinical functions include attending to patients, examination and administering medical treatment to patients and performing minor outpatient surgical procedures, prescribing medicines and investigations, such as laboratory tests or diagnostic procedures. These clinical functions also include the review of investigation results and follow-up care with the patient. It provides medical oncology services and palliative care services with approximately 13 doctors at over eight clinics.
(Source: https://www.sgx.com/securities/equities/5G3)

Securities Investors Association (Singapore)
7 Maxwell Road #05-03 MND Building Annexe B Singapore 069111
Tel: (65) 6227 2683 Fax: (65) 6220 6614
Email: admin@sias.org.sg www.sias.org.sg
UEN No: S99SS0111B
GST Reg No: M90367530Y

Q1. In the Message to shareholders (pages 5-6 of the annual report), the group's PRC growth strategy was discussed in detail. The new Sino-Singapore oncology hospital in Chongqing is expected to start operations in the second half of 2020 while the group is also setting up a medical centre of international standards that will focus on cancer treatment and other medical services in Beijing.

(i) **Can management help shareholders understand who is leading the group's expansion in the PRC?**

(ii) **When is the Beijing Medical Centre expected to open its doors?**

(iii) **What is the collective experience of the board and management in setting up and running medical facilities in the PRC? How does the group pro-actively manage any potential expectation gaps and cultural and professional differences?**

Q2. The group has invested in CellVec Pte. Ltd. which is in the area of cellular and gene therapy services and Stem Med Pte. Ltd. which is involved in stem cell processing and storage services. As seen in Note 13 (page 80 – Investment in subsidiaries), Stem Med's revenue increased by 63% to $2.17 million while CellVec reported its first revenue of $479,000 for FY2019. Stem Med narrowed its losses to $(467,000) but CellVec's loss for the year increased to $(6.3) million. Both subsidiaries are in net liability position of $(2.8) million and $(4.8) million respectively.

(i) **Can the company help shareholders understand the synergy and/or strategic value of Stem Med and CellVec to the group's core oncology services?**

(ii) **How much more in investment has the company earmarked to support Stem Med and CellVec?**

(iii) **When are the two subsidiaries expected to breakeven?**

Q3. Mr Lim Teong Jin George is a non-executive director of the company and was first appointed to the board on 23 December 2013. Mr George Lim is also a member of the remuneration committee and a member of the committee that administers the TalkMed Group Employee Share Option Scheme (the "ESOS") and the TalkMed Group Performance Share Plan (the "PSP"). Mr George Lim's profile could be found on page 12 of the annual report.

(i) **Would the nominating committee help shareholders understand the reason(s) Mr Lim has been deemed non-independent?**

Securities Investors Association (Singapore)
7 Maxwell Road #05-03 MND Building Annexe B Singapore 069111
Tel: (65) 6227 2683 Fax: (65) 6220 6614
Email: admin@sias.org.sg www.sias.org.sg
UEN No: S99SS0111B
GST Reg No: M90367530Y

^Amid the global COVID-19 outbreak, issuers who choose to proceed with the AGM before 30 April 2020 must provide opportunities for shareholders to ask questions. Shareholders are encouraged to read the annual report and submit any questions they might have to the companies in advance. Issuers would then publicly address the questions at the general meeting via the issuer's website, through "live" webcast and on SGXNet.

Shareholders are welcome to use and/or adapt the questions prepared by SIAS and to forward them to the company.

Can't attend the AGM or view the webcast? Check out the latest questions on the annual reports of listed companies on SIAS website

Join our mailing list here to receive latest news and upcoming events.

CONNECT WITH US

^ Joint Statement by Accounting and Corporate Regulatory Authority, Monetary Authority of Singapore and Singapore Exchange Regulation dated 31 Mar 2020 (https://www.sgx.com/media-centre/20200331-acra-mas-and-sgx-regco-update-guidance-general-meetings)